Top Markets
#1 Naoris Protocol Naoris Protocol +19.86%
#2 pippin pippin +15.85%
#3 IQ IQ +14.14%
#4 peaq peaq +11.65%
#5 Bedrock Bedrock +11.38%
#6 Ridges AI Ridges AI +9.13%
#7 Chrema Coin Chrema Coin +7.92%
#8 FLOCK FLOCK +7.88%
#9 Bittensor Bittensor +7.58%
#10 affine affine +7.57%
Coin of the day
Naoris Protocol Naoris Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Medtronic plc Medtronic plc

Medtronic plc

2M6
Rangering i aksjer #166
Medtronic plc develops, manufactures, and sells device-based medical therapies... Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Aksjekurs
$88.76
Markedsverdi
$113.96B
Endring (1 dag)
-0.15%
Endring (1 år)
-1.87%
Land
IE
Handel Medtronic plc (2M6)

Kategori

Healthcare
P/E-forhold for Medtronic plc (2M6)
P/E-forhold per 2026 TTM: 0
Ifølge Medtronic plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Medtronic plc fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 28.93 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 39.68 -
US
Medtronic Medtronic
Medtronic
MDT.US
 24.21 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 35.47 -
US
Siemens Healthineers AG Siemens Healthineers AG
Siemens Healthineers AG
SMMNY.US
 20.43 -
DE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.